DrugBiological
Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes clinical trials
Keep track of what changes. Save the Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
6 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 0
Cartesian Therapeutics (6)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes is read from its arms, and is right about nine times in ten.
Testing it · 6
- Descartes-08 in Autoantibody MyositisRecruitingPhase 2Cartesian TherapeuticsNCT07391605Written as Descartes-08
- Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersRecruitingPhase 1/2Cartesian TherapeuticsNCT07089121Written as Descartes-08
- Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)Active, not recruitingPhase 2Cartesian TherapeuticsNCT04146051Written as Descartes-08
- Descartes-08 for Patients With Systemic Lupus ErythematosusActive, not recruitingPhase 2Cartesian TherapeuticsNCT06038474Written as Descartes-08
- Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyTerminatedPhase 2Cartesian TherapeuticsNCT04816526Written as Descartes 08
- Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With MyelomaTerminatedPhase 1Cartesian TherapeuticsNCT03448978Written as Descartes-08